Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

NCT03647956 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IIIB
NSCLC Stage IV
EGFR Activating Mutation

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

The University of Hong Kong